All Stories

  1. The structure of a NEMO construct engineered for screening reveals novel determinants of inhibition
  2. The structure of a NEMO construct engineered for screening reveals novel determinants of inhibition
  3. An engineered construct of cFLIP provides insight into DED1 structure and interactions
  4. A disulfide constrains the ToxR periplasmic domain structure, altering its interactions with ToxS and bile-salts
  5. A guide to prepare and crystallize the N-terminal domain of NEMO
  6. The structure of a highly conserved picocyanobacterial protein reveals a Tudor domain with an RNA binding function
  7. The structure of the unbound IKK-binding domain of NEMO
  8. A pseudo-receiver domain in Atg32 is required for mitophagy
  9. Cysteine modifiers suggest an allosteric inhibitory site on the CAL PDZ domain
  10. Backbone and side chain resonance assignments for a structured domain within Atg32
  11. A small molecule ligand for AphB increases activity
  12. The Peach RGF/GLV Signalling Peptide pCTG134 Is Involved In A Regulatory Circuit That Sustains Auxin And Ethylene Actions
  13. Cholera toxins ToxR and ToxS interact and are affected by bile salts and pH.
  14. A new class of inhibitors of the AraC family virulence regulator Vibrio cholerae ToxT
  15. Identification and Characterization of the Interaction Site between cFLIPL and Calmodulin
  16. A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death
  17. Small-molecule inhibitors of JC polyomavirus infection
  18. Phosphorylation of Ezrin-Radixin-Moesin-binding Phosphoprotein 50 (EBP50) by Akt Promotes Stability and Mitogenic Function of S-phase Kinase-associated Protein-2 (Skp2)
  19. Protein Engineering of the N-Terminus of NEMO: Structure Stabilization and Rescue of IKKβ Binding
  20. Small Molecule Inhibition of the Na+/H+ Exchange Regulatory Factor 1 and Parathyroid Hormone 1 Receptor Interaction
  21. Monitoring ATP hydrolysis and ATPase inhibitor screening using1H NMR
  22. Engineering a soluble parathyroid hormone GPCR mimetic
  23. Recombinant production of TEV cleaved human parathyroid hormone
  24. Structure of the extracellular domains of human andXenopusFn14: implications in the evolution of TWEAK and Fn14 interactions
  25. Reining in Polyoma Virus Associated Nephropathy: Design and Characterization of a Template Mimicking BK Viral Coat Protein Cellular Binding
  26. A Stabilizing Influence: CAL PDZ Inhibition Extends the Half-Life of ΔF508-CFTR
  27. A Stabilizing Influence: CAL PDZ Inhibition Extends the Half-Life of ΔF508-CFTR
  28. ChemInform Abstract: Parathyroid Hormone and Parathyroid Hormone-Related Protein: Model Systems for the Development of an Osteoporosis Therapy
  29. Pharmacological stabilization of ΔF508-CFTR at the cell surface: design of CAL-selective PDZ inhibitors
  30. Structure of Vibrio cholerae ToxT reveals a mechanism for fatty acid regulation of virulence genes
  31. Structural analysis of the human cannabinoid receptor one carboxyl‐terminus identifies two amphipathic helices
  32. Structure of a NEMO/IKK-Associating Domain Reveals Architecture of the Interaction Site
  33. Structural characterization of the parathyroid hormone receptor domains determinant for ligand binding
  34. N-Terminally PEGylated Human Interferon-β-1a with Improved Pharmacokinetic Properties and in Vivo Efficacy in a Melanoma Angiogenesis Model
  35. The Δe13 Isoform of the Calcitonin Receptor Forms a Six-Transmembrane Domain Receptor with Dominant-Negative Effects on Receptor Surface Expression and Signaling
  36. A 13C NMR approach to categorizing potential limitations of α,β-unsaturated carbonyl systems in drug-like molecules
  37. Receptor–Ligand Interactions
  38. Toward Parathyroid Hormone Minimization:  Conformational Studies of Cyclic PTH(1−14) Analogues
  39. NMR studies of CCK-8/CCK1complex support membrane-associated pathway for ligand-receptor interaction
  40. The PDZ1 Domain of SAP90: CHARACTERIZATION OF STRUCTURE AND BINDING
  41. Structural characterization of lipopeptide agonists for the bradykinin B2 receptor
  42. Molecular Characterization of the Substance P{middle dot}Neurokinin-1 Receptor Complex: DEVELOPMENT OF AN EXPERIMENTALLY BASED MODEL
  43. Photoaffinity Labeling of Mutant Neurokinin-1 Receptors Reveals Additional Structural Features of the Substance P/NK-1 Receptor Complex
  44. Structural characterization of lipopeptide agonists for the bradykinin B2 receptor
  45. CtrΔe13, a Calcitonin Receptor Isoform Lacking 14 Amino Acids in Transmembrane Helix 7: Structure and Topology
  46. Characterizing the Interactions Between Cholecystokinin and the G-Protein Coupled Receptors CCK1 and CCK2: An NMR-Based Study
  47. Probing the Importance of the N-Terminal Helix of Parathyroid Hormone: Introduction of Cyclohexylalanine to Tether to the Membrane
  48. Agonist Activity at the Kinin B1 Receptor:  Structural Requirements of the Central Tetrapeptide
  49. Structure-Based Optimization of Peptide Inhibitors of Mammalian Ribonucleotide Reductase,
  50. Molecular Complex of Cholecystokinin-8 and N-Terminus of the Cholecystokinin A Receptor by NMR Spectroscopy
  51. Expression and Spectroscopic Analysis of Soluble Nicotinic Acetylcholine Receptor Fragments Derived from the Extracellular Domain of the α-Subunit †
  52. Probing the Topological Arrangement of the N- and C-Terminal Residues of Bradykinin for Agonist Activity at the B1 Receptor
  53. Molecular Characterization of the Receptor−Ligand Complex for Parathyroid Hormone
  54. Structural characterization of peptide hormone/receptor interactions by NMR spectroscopy
  55. Structural characterization of peptide hormone/receptor interactions by NMR spectroscopy
  56. Motif Mutation of Bradykinin B2 Receptor Second Intracellular Loop and Proximal C Terminus Is Critical for Signal Transduction, Internalization, and Resensitization
  57. Parathyroid Hormone-Receptor Interactions Identified Directly by Photocross-linking and Molecular Modeling Studies
  58. Binding Domain of Human Parathyroid Hormone Receptor:  From Conformation to Function,
  59. 1,2,5-Trisubstituted 1,4-diazepine-3-one: A novel dipeptidomimetic molecular scaffold
  60. Conformational investigation of a novel dipeptide based molecular scaffold
  61. Addressing the Tertiary Structure of Human Parathyroid Hormone-(1-34)
  62. Structure, dynamics, and topological orientation of the polyether, ionophore antibiotic monensin, in a micellar environment
  63. Structure, dynamics, and topological orientation of the polyether, ionophore antibiotic monensin, in a micellar environment
  64. Conformational Studies of RS-66271, an Analog of Parathyroid Hormone-Related Protein with Pronounced Bone Anabolic Activity
  65. Conformational consequences of i, i + 3 cystine linkages: nucleation for α‐helicity?
  66. Synthesis of a Trisubstituted 1,4-Diazepin-3-one-Based Dipeptidomimetic as a Novel Molecular Scaffold
  67. A Trisubstituted 1,4-Diazepine-3-one-Based Dipeptidomimetic:  Conformational Characterization by NMR and Computer Simulation
  68. Threonine6-Bradykinin:  Molecular Dynamics Simulations in a Biphasic Membrane Mimetic
  69. Threonine6-Bradykinin:  Structural Characterization in the Presence of Micelles by Nuclear Magnetic Resonance and Distance Geometry
  70. Threonine6-bradykinin: Conformational study of a flexible peptide in dimethyl sulfoxide by NMR and ensemble calculations
  71. Peptide Mimetic of the Third Cytoplasmic Loop of the PTH/PTHrP Receptor
  72. Threonine6‐bradykinin: Conformational study of a flexible peptide in dimethyl sulfoxide by NMR and ensemble calculations
  73. Conformational characterization of a peptide mimetic of the third cytoplasmic loop of the G-protein coupled parathyroid hormone/parathyroid hormone related protein receptor
  74. Conformation of cyclobradykinin by nmr and distance geometry calculations
  75. Conformation of parathyroid hormone antagonists by CD, nmr, and molecular dynamics simulations
  76. RS-66271, a clinical candidate derived from parathyroid hormone related protein: The role of enhanced amphiphilic helicity
  77. Molecular characterization of the interaction between parathyroid hormone and its receptor
  78. Lactam cyclization [i to (i+4)] for nucleation/stabilization of α-helices?
  79. Identification and exploitation of structural foci that influence conformational mobility in somatostatin agonists and antagonists
  80. Secondary and tertiary fold of the human parathyroid hormone1–34 in different environments as a pathway to bioactive conformation